Efficacy and safety of Tildrakizumab in Australian patients with chronic plaque psoriasis in a phase 3 clinical trial

被引：0
|
作者：
Foley, P. [1 ,2 ]
Spelman, L. [3 ,4 ]
Fernandez-Penas, P. [5 ,6 ]
Freeman, M. [7 ]
Sinclair, R. [8 ]
Horton, J. [9 ]
Rozzo, S. J. [10 ]
Kurstjens, N. [11 ]
Shumack, S. [12 ]
机构：
[1] Skin & Canc Fdn Inc, Carlton, Vic, Australia
[2] Prob Med Res, Carlton, Vic, Australia
[3] Verac Clin Res, Brisbane, Qld, Australia
[4] Prob Med Res, Brisbane, Qld, Australia
[5] Westmead Hosp, Dept Dermatol, Westmead, NSW, Australia
[6] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[7] Skin Ctr, Benowa, Qld, Australia
[8] Univ Melbourne, Melbourne, Vic, Australia
[9] Forest Hill Dermatol & Skin Canc Clin, Forest Hill, Vic, Australia
[10] Sun Pharmaceut Ind Inc, Princeton, NJ USA
[11] Sun Pharma ANZ, Macquarie Pk, NSW, Australia
[12] Univ Sydney, Sydney, NSW, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2021年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1
    Tyring, S.
    Spelman, L.
    Igarashi, A.
    Ohtsuki, M.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Guenthner, S.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 61
  • [22] Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial
    Eichenfield, Lawrence F.
    Tarabar, Sanela
    Forman, Seth
    Garcia-Bello, Alfonso
    Feng, Gang
    Fetterly, Gerald
    Mahling, Ping
    Peeva, Elena
    Vincent, Michael S.
    Chandra, Deepa E.
    [J]. JAMA DERMATOLOGY, 2024, 160 (02) : 156 - 163
  • [23] Safety of tildrakizumab in a Phase 4 real-world study in patients with moderate-to-severe plaque psoriasis
    Vasquez, J. Gabriel
    Bhatia, Neal
    Schenkel, Brad
    Rozzo, Stephen J.
    Heim, Jayme
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB85 - AB85
  • [24] Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    Strober, B. E.
    Crowley, J. J.
    Yamauchi, P. S.
    Olds, M.
    Williams, D. A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (03) : 661 - 668
  • [25] Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
    Ohtsuki, Mamitaro
    Fujita, Hideki
    Watanabe, Mitsunori
    Suzaki, Keiko
    Flack, Mary
    Huang, Xin
    Kitamura, Susumu
    Valdes, Joaquin
    Igarashi, Atsuyuki
    [J]. JOURNAL OF DERMATOLOGY, 2019, 46 (08): : 686 - 694
  • [26] Incidence of infections in clinical trials of tildrakizumab for moderate-to-severe chronic plaque psoriasis
    Crowley, Jeffrey
    Leonardi, Craig
    Sturgill-Koszycki, Sheila
    Menter, Alan
    Mendelsohn, Alan M.
    Li, Qing
    Cichanowitz, Nicole
    Gree, Stuart
    la Rosa, Carmen
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB166 - AB166
  • [27] Impact of body weight on efficacy of tildrakizumab at week 12 in moderate to severe chronic plaque psoriasis
    Blauvelt, A.
    Kimball, A.
    Papp, K.
    Reich, K.
    Tyring, S.
    Sinclair, R.
    Thaci, D.
    Li, Q.
    Cichanowitz, N.
    Green, S.
    La Rosa, C.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 109 - 110
  • [28] Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis
    Elewski, Boni
    Menter, Alan
    Crowley, Jeffrey
    Tyring, Stephen
    Zhao, Yang
    Lowry, Simon
    Rozzo, Stephen
    Mendelsohn, Alan M.
    Parno, Jeffrey
    Gordon, Kenneth
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (08) : 763 - 768
  • [29] PREDICTORS OF RESPONSE TO TILDRAKIZUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
    Blauvelt, Andrew
    Reich, Kristian
    Papp, Kim A.
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Gooderham, Melinda
    Li, Qing
    Cichanowitz, Nicole
    La Rosa, Carmen
    [J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 22 - 22
  • [30] A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis
    Spelman, Lynda
    Rubel, Diana
    Brnabic, Alan
    Burkhardt, Nicole
    Riedl, Elisabeth
    Foley, Peter
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 329 - 335
12345